文献速递消化系统肿瘤

结直肠癌统计,2023年

Colorectal cancer statistics, 2023.
PubMed 文献 · CA Cancer J Clin · 2023-03-01

美国癌症协会基于人群癌症登记处的发病率和国家卫生统计中心的死亡率,每3年更新一次结直肠癌(CRC)统计。2023年约153020人被诊断为CRC、52550人死于该病,其中50岁以下19550例、3750例死亡;总体发病与死亡率下降,但诊断正快速转向更年轻、更晚期和左半结肠/直肠。

要点

  • 2023年美国约153020例新发CRC、52550例死亡,其中50岁以下19550例和3750例死亡。
  • 55岁以下人群发病率自1990年代中期起每年增加1%-2%,该人群病例占比从1995年11%升至2019年20%。
  • 总体死亡率2011-2020年每年下降2%,但50岁以下人群和65岁以下美洲原住民每年增加0.5%-3%。

核心结论

  • 尽管总体发病率和死亡率持续下降,CRC正快速转向更年轻年龄、更晚期阶段和左半结肠/直肠诊断。
  • 揭示1950年以来出生世代发病率上升的病因并提高所有人群(尤其美洲原住民)获得高质量筛查和治疗的机会,可能加速CRC防治进展。

研究设计与样本

  • 美国癌症协会每3年一次基于人群癌症登记处发病率与国家卫生统计中心死亡率的CRC统计更新。
  • 2023年估计约153020人被诊断为CRC,52550人死于该病。

主要发现

  • 2023年50岁以下人群估计19550例新发病例和3750例死亡。
  • CRC发病率下降速度从2000年代的每年3%-4%放缓至2011-2019年的每年1%。
  • 55岁以下人群发病率自1990年代中期起每年增加1%-2%。
  • 55岁以下人群病例占比从1995年11%升至2019年20%。
  • 约2010年以来,65岁以下人群区域期疾病发病率每年增加约2%-3%,远处转移期疾病每年增加0.5%-3%,逆转了1995-2005年整体向早期诊断转变的趋势。

关键数值与推荐

  • 2023年估计CRC新发153020例、死亡52550例,其中50岁以下19550例和3750例死亡。
  • 55岁以下人群病例占比由1995年11%升至2019年20%。
  • 2019年全部新发病例中晚期占60%,2000年代中期为52%,1995年为57%。
  • 直肠癌占比由1995年27%升至2019年31%。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Colorectal cancer (CRC) is the second most common cause of cancer death in the United States. Every 3 years, the American Cancer Society provides an update of CRC statistics based on incidence from population-based cancer registries and mortality from the National Center for Health Statistics. In 2023, approximately 153,020 individuals will be diagnosed with CRC and 52,550 will die from the disease, including 19,550 cases and 3750 deaths in individuals younger than 50 years. The decline in CRC incidence slowed from 3%-4% annually during the 2000s to 1% annually during 2011-2019, driven partly by an increase in individuals younger than 55 years of 1%-2% annually since the mid-1990s. Consequently, the proportion of cases among those younger than 55 years increased from 11% in 1995 to 20% in 2019. Incidence since circa 2010 increased in those younger than 65 years for regional-stage disease by about 2%-3% annually and for distant-stage disease by 0.5%-3% annually, reversing the overall shift to earlier stage diagnosis that occurred during 1995 through 2005. For example, 60% of all new cases were advanced in 2019 versus 52% in the mid-2000s and 57% in 1995, before widespread screening. There is also a shift to left-sided tumors, with the proportion of rectal cancer increasing from 27% in 1995 to 31% in 2019. CRC mortality declined by 2% annually from 2011-2020 overall but increased by 0.5%-3% annually in individuals younger than 50 years and in Native Americans younger than 65 years. In summary, despite continued overall declines, CRC is rapidly shifting to diagnosis at a younger age, at a more advanced stage, and in the left colon/rectum. Progress against CRC could be accelerated by uncovering the etiology of rising incidence in generations born since 1950 and increasing access to high-quality screening and treatment among all populations, especially Native Americans.

来源:CA Cancer J Clin,查看原文。版权归原作者所有。

引用

  1. Siegel RL, Wagle NS, Cercek A, et al. Colorectal cancer statistics, 2023. CA Cancer J Clin. 2023. PMID: 36856579. doi:10.3322/caac.21772

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。